Raina Rupesh, Lakin Milton M, Agarwal Ashok, Sharma Rakesh, Goyal Kush K, Montague Drogo K, Klein Eric, Zippe Craig D
Glickman Urological Institute, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA.
Urology. 2003 Jul;62(1):110-5. doi: 10.1016/s0090-4295(03)00157-2.
To evaluate the long-term effect and safety of sildenafil citrate for the treatment of erectile dysfunction after radical prostatectomy (RP).
The study consisted of 91 patients with erectile dysfunction from our institution who received oral sildenafil citrate after RP. We surveyed these patients using a self-administered questionnaire during the first year of sildenafil citrate use to determine treatment satisfaction, patient compliance, and safety. Those who had responded positively to the drug were surveyed again 3 years later (n = 48). Sildenafil citrate was prescribed at a dose of 50 mg and increased to 100 mg if needed. Data were collected from a self-administered questionnaire using the abridged five-item version of the International Index of Erectile Function questionnaire, referred to as the Sexual Health Inventory of Men, and the Erectile Dysfunction Inventory of Treatment Satisfaction. The patients were stratified according to the type of nerve-sparing (NS) RP procedure they underwent: bilateral NS, unilateral NS, and non-NS.
At 3 years, 31 (71%) of the 43 patients who had returned the second surveys were still responding to sildenafil. Of these 31 respondents, 10 (31%) had augmented their dose from 50 to 100 mg. The dropout rate was 27%; 6 of 12 had discontinued because of the return of natural erections, 5 because of a loss of efficacy, and 1 because his spouse had died. No differences were found in the 1-year and 3-year five-item International Index of Erectile Function (Sexual Health Inventory of Men) and Erectile Dysfunction Inventory of Treatment Satisfaction scores between the NS groups. The most common side effects at 3 years were headache (12%), flushing (10%), and blue or blurred vision (2%). No patient discontinued the drug at 3 years because of side effects.
The results of this study indicate that the vast majority of patients with erectile dysfunction after RP who initially respond to sildenafil continue to do so at 3 years and are satisfied and compliant with the treatment regimen.
评估枸橼酸西地那非治疗前列腺癌根治术(RP)后勃起功能障碍的长期疗效和安全性。
本研究纳入了我院91例RP后出现勃起功能障碍且接受口服枸橼酸西地那非治疗的患者。在使用枸橼酸西地那非的第一年,我们通过自行填写问卷的方式对这些患者进行调查,以确定治疗满意度、患者依从性和安全性。对药物反应呈阳性的患者在3年后再次接受调查(n = 48)。枸橼酸西地那非的初始剂量为50 mg,必要时可增至100 mg。数据通过自行填写问卷收集,问卷采用国际勃起功能指数问卷的简化五项版本,即男性性健康量表,以及治疗满意度勃起功能障碍量表。患者根据所接受的神经保留(NS)RP手术类型进行分层:双侧NS、单侧NS和非NS。
在3年时,43例返回第二次调查的患者中有31例(71%)仍对西地那非有反应。在这31例有反应的患者中,10例(31%)将剂量从50 mg增至100 mg。脱落率为27%;12例中有6例因自然勃起恢复而停药,5例因疗效丧失而停药,1例因配偶死亡而停药。NS组之间在1年和3年的五项国际勃起功能指数(男性性健康量表)和治疗满意度勃起功能障碍量表评分上未发现差异。3年时最常见的副作用是头痛(12%)、面部潮红(10%)和视物发蓝或模糊(2%)。3年时没有患者因副作用而停药。
本研究结果表明,绝大多数RP后勃起功能障碍且最初对西地那非有反应的患者在3年时仍有反应,并且对治疗方案满意且依从。